ClinVar Miner

Submissions for variant NM_000260.4(MYO7A):c.3719G>A (p.Arg1240Gln) (rs111033178)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000623302 SCV000741118 pathogenic Inborn genetic diseases 2014-09-07 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: POSITIVE: Relevant Alteration(s) Detected
CeGaT Praxis fuer Humangenetik Tuebingen RCV000256123 SCV000608608 likely pathogenic not provided 2017-02-28 criteria provided, single submitter clinical testing
Counsyl RCV000664885 SCV000788911 pathogenic Deafness, autosomal recessive 2; Usher syndrome, type 1 2017-01-03 criteria provided, single submitter clinical testing
Fulgent Genetics,Fulgent Genetics RCV000763279 SCV000893923 pathogenic Deafness, autosomal dominant 11; Deafness, autosomal recessive 2; Usher syndrome, type 1 2018-10-31 criteria provided, single submitter clinical testing
GeneDx RCV000256123 SCV000321919 pathogenic not provided 2018-05-17 criteria provided, single submitter clinical testing The R1240Q variant in the MYO7A gene has been reported previously in association with Usher syndrome (Bharadwaj et al., 2000; Pennings et al., 2004; Roux et al., 2006; Jacobson et al., 2008). The variant was not observed at any significant frequency in approximately 6300 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. R1240Q is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species, and in silico analysis predicts this variant is probably damaging to the protein structure/function. Therefore, this variant is pathogenic.
GeneReviews RCV000036122 SCV000268744 pathogenic Usher syndrome, type 1 2016-05-19 no assertion criteria provided literature only
Illumina Clinical Services Laboratory,Illumina RCV000778342 SCV000914542 pathogenic MYO7A-Related Disorders 2018-10-05 criteria provided, single submitter clinical testing The MYO7A c.3719G>A (p.Arg1240Gln) missense variant has been reported in at least 11 studies in which it is found in 26 individuals with Usher syndrome type 1 including five homozygotes, 18 compound heterozygotes, two heterozygotes, and in one individual in a double heterozygous state with a variant in the USH2A gene (Janecke et al. 1999; Bharadwaj et al. 2000; Pennings et al. 2004; Gerber et al. 2006; Pennings et al. 2006; Roux et al. 2006; Jaijo et al. 2007; Jacobsen et al. 2008; Jaijo et al. 2010; Bonnet et al. 2011; Le Quesne Stabej et al. 2012). While this variant has not been reported in conjunction with nonsyndromic hearing loss, disease risk cannot be ruled out. The variant was not found in at least 1075 healthy controls (Janecke et al. 1999; Roux et al. 2006; Jaijo et al. 2010; Bonnet et al. 2011) and is reported at a frequency of 0.000723 in the European (non-Finnish) population of the Exome Aggregation Consortium. Based on the combined evidence, the p.Arg1240Gln variant is classified as pathogenic for Usher syndrome. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Invitae RCV000256123 SCV000955876 pathogenic not provided 2018-11-19 criteria provided, single submitter clinical testing This sequence change replaces arginine with glutamine at codon 1240 of the MYO7A protein (p.Arg1240Gln). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and glutamine. This variant is present in population databases (rs111033178, ExAC 0.2%). This variant has been observed to be homozygous or in combination with another MYO7A variant in individuals affected with Usher syndrome or with clinical features of this condition (PMID: 22135276, 20513143, 21569298, 17361009, 10930322, 21873662, 18463160, 15043528, 16652077) or with non-syndromic deafness (PMID: 27068579, 26969326). In one of these individuals, the variant has been observed on the opposite chromosome (in trans) from a pathogenic variant. This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 43218). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. This variant disrupts the p.Arg1240 amino acid residue in MYO7A. Other variant(s) that disrupt this residue have been observed in affected individuals (PMID: 24199935), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000844719 SCV000059774 pathogenic Rare genetic deafness 2010-12-21 criteria provided, single submitter clinical testing The Arg1240Gln variant in MYO7A has been reported in at least 14 probands with U sher syndrome (Jacobson 2008, Bharadwaj 2000, Gerber 2006, Jaijo 2007, Jaijo 200 9, Janecke 1999, Pennings 2006, Pennings 2004, Roux 2006). Eleven of these proba nds were homozygous or compound heterozygous. In summary, this variant meets our criteria to be classified as pathogenic.
NIHR Bioresource Rare Diseases, University of Cambridge RCV000504703 SCV000599121 likely pathogenic Usher syndrome 2015-01-01 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.